Posted by Michael Wonder on 14 Jan 2024
FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 stage III-IVA cervical cancer
15 January 2024 - On 12 January 2024, the FDA approved pembrolizumab (Keytruda) with chemoradiotherapy for patients with FIGO 2014 stage III-IVA cervical cancer.
Efficacy was evaluated in KEYNOTE-A18, a multi-centre, randomised, double-blind, placebo-controlled trial enrolling 1,060 patients with cervical cancer who had not previously received definitive surgery, radiation, or systemic therapy.
